Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Interest & Investment Income (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Interest & Investment Income data on record, last reported at $3.6 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 96.74% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $10.7 million, down 23.31%, while the annual FY2025 figure was $11.3 million, 19.23% down from the prior year.
  • Interest & Investment Income reached $3.6 million in Q4 2025 per COLL's latest filing, up from $3.1 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.5 million in Q3 2023 and bottomed at $3000.0 in Q1 2021.
  • Average Interest & Investment Income over 5 years is $2.1 million, with a median of $2.2 million recorded in 2025.
  • Peak YoY movement for Interest & Investment Income: plummeted 98.58% in 2021, then soared 80440.0% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $3000.0 in 2021, then soared by 34133.33% to $1.0 million in 2022, then soared by 318.99% to $4.3 million in 2023, then tumbled by 57.89% to $1.8 million in 2024, then soared by 96.74% to $3.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $3.6 million in Q4 2025, $3.1 million in Q3 2025, and $2.2 million in Q1 2025.